Disc Medicine (IRON) Stock Forecast & Price Target

Compare

504 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRON Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Disc

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRON Stock 12 Month Forecast

Average Price Target

$112.71

▲(25.32% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $112.71 with a high forecast of $153.00 and a low forecast of $90.00. The average price target represents a 25.32% change from the last price of $89.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","73":"$73","100":"$100","127":"$127","154":"$154"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$153.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,73,100,127,154],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,73.6523076923077,80.26461538461538,86.87692307692308,93.48923076923077,100.10153846153847,106.71384615384616,113.32615384615384,119.93846153846154,126.55076923076923,133.16307692307691,139.7753846153846,146.3876923076923,{"y":153,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,70.55307692307693,74.06615384615385,77.57923076923078,81.0923076923077,84.60538461538462,88.11846153846153,91.63153846153847,95.14461538461538,98.65769230769232,102.17076923076922,105.68384615384616,109.19692307692307,{"y":112.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.04,68.80615384615385,70.5723076923077,72.33846153846154,74.10461538461539,75.87076923076924,77.63692307692308,79.40307692307692,81.16923076923078,82.93538461538462,84.70153846153846,86.46769230769232,88.23384615384616,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$153.00

Average Price Target$112.71

Lowest Price Target$90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Smith

Leerink Partners

$85→$100

Buy

11.19%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)With the FDA’s new CNPV and improved outlook for bitopertin in EPP, we increase our PT to $100 and reiterate our Outperform rating.

Rami Katkhuda

LifeSci Capital

$85→$110

Buy

22.30%

Upside

Reiterated

10/17/25

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM) and Disc Medicine (NASDAQ: IRON)OUTPERFORM | PRICE TARGET: $110.00 … updating our price target to $110/share

Douglas Tsao

H.C. Wainwright

$118

Buy

31.20%

Upside

Reiterated

10/17/25

Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch

David Nierengarten

Wedbush

$90→$110

Buy

22.30%

Upside

Reiterated

10/17/25

Disc Medicine price target raised to $110 from $90 at WedbushDisc Medicine price target raised to $110 from $90 at Wedbush

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

10/17/25

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV) and Disc Medicine (NASDAQ: IRON)

Martin Auster

Raymond James

$89→$108

Buy

20.08%

Upside

Reiterated

10/17/25

Disc Medicine price target raised to $108 from $89 at Raymond JamesDisc Medicine price target raised to $108 from $89 at Raymond James

Kristen Kluska

Cantor Fitzgerald

$132→$153

Buy

70.11%

Upside

Reiterated

10/16/25

Cantor Fitzgerald Sticks to Their Buy Rating for Disc Medicine (IRON)

Sean Laaman

Morgan Stanley

$90

Buy

0.07%

Upside

Reiterated

10/03/25

Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP TreatmentWe hosted a KOL call with a hepatologist, who is a leading clinical researcher and practicing physician, to discuss the treatment landscape for Erythropoietic Porphyrias (EPP and XLP) as well as specific impressions of Disc Medicine's bitopertin, following the recent NDA submission. Our KOL is a professor, clinical researcher, and physician, specializing in hepatology at a major academic center. His clinical practice is focused on liver and metabolic disorders, including disorders relating to iron, porphyrin and heme metabolism. He shared his experience in the treatment of erythropoietic porphyrias, namely Erythropoietic Protoporphyria (EPP), and impressions of Disc Medicine's bitopertin, a treatment that is currently being considered for FDA approval for the treatment of EPP.

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/07/25

Disc Medicine (IRON) Receives a Buy from TD Cowen

Greg Harrison

Scotiabank

$75

Buy

-16.61%

Downside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Evan Seigerman

BMO Capital

$120

Buy

33.42%

Upside

Reiterated

06/17/25

BMO Capital Reaffirms Their Buy Rating on Disc Medicine (IRON)

Tiago Fauth

Wells Fargo

$91

Buy

1.18%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Disc Medicine (NASDAQ: IRON)

Roger Song

Jefferies

$111

Buy

23.42%

Upside

Reiterated

03/13/25

Disc Medicine's Strategic Advances and Market Potential Drive Positive Analyst Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Smith

Leerink Partners

$85→$100

Buy

11.19%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)With the FDA’s new CNPV and improved outlook for bitopertin in EPP, we increase our PT to $100 and reiterate our Outperform rating.

Rami Katkhuda

LifeSci Capital

$85→$110

Buy

22.30%

Upside

Reiterated

10/17/25

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM) and Disc Medicine (NASDAQ: IRON)OUTPERFORM | PRICE TARGET: $110.00 … updating our price target to $110/share

Douglas Tsao

H.C. Wainwright

$118

Buy

31.20%

Upside

Reiterated

10/17/25

Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch

David Nierengarten

Wedbush

$90→$110

Buy

22.30%

Upside

Reiterated

10/17/25

Disc Medicine price target raised to $110 from $90 at WedbushDisc Medicine price target raised to $110 from $90 at Wedbush

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

10/17/25

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV) and Disc Medicine (NASDAQ: IRON)

Martin Auster

Raymond James

$89→$108

Buy

20.08%

Upside

Reiterated

10/17/25

Disc Medicine price target raised to $108 from $89 at Raymond JamesDisc Medicine price target raised to $108 from $89 at Raymond James

Kristen Kluska

Cantor Fitzgerald

$132→$153

Buy

70.11%

Upside

Reiterated

10/16/25

Cantor Fitzgerald Sticks to Their Buy Rating for Disc Medicine (IRON)

Sean Laaman

Morgan Stanley

$90

Buy

0.07%

Upside

Reiterated

10/03/25

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/07/25

Disc Medicine (IRON) Receives a Buy from TD Cowen

Greg Harrison

Scotiabank

$75

Buy

-16.61%

Downside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Evan Seigerman

BMO Capital

$120

Buy

33.42%

Upside

Reiterated

06/17/25

BMO Capital Reaffirms Their Buy Rating on Disc Medicine (IRON)

Tiago Fauth

Wells Fargo

$91

Buy

1.18%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Disc Medicine (NASDAQ: IRON)

Roger Song

Jefferies

$111

Buy

23.42%

Upside

Reiterated

03/13/25

Disc Medicine's Strategic Advances and Market Potential Drive Positive Analyst Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Disc Medicine

1 Month

xxx

Success Rate

13/17 ratings generated profit

Average Return

+9.94%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +9.94% per trade.

3 Months

xxx

Success Rate

17/21 ratings generated profit

Average Return

+22.69%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +22.69% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

19/21 ratings generated profit

Average Return

+24.12%

reiterated a buy rating 2 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +24.12% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+51.86%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +51.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRON Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRON has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRON average Analyst price target in the past 3 months is 112.71.

Each month's total comprises the sum of three months' worth of ratings.

IRON Financial Forecast

IRON Earnings Forecast

Next quarter’s earnings estimate for IRON is -$1.49 with a range of -$1.74 to -$1.18. The previous quarter’s EPS was -$1.58. IRON beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IRON has Preformed in-line its overall industry.

No data currently available

IRON Sales Forecast

Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IRON has Preformed in-line its overall industry.

IRON Stock Forecast FAQ

What is IRON’s average 12-month price target, according to analysts?

Based on analyst ratings, Disc Medicine’s 12-month average price target is 112.71.

What is IRON’s upside potential, based on the analysts’ average price target?

Disc Medicine has 25.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRON a Buy, Sell or Hold?

Disc Medicine has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Disc Medicine’s price target?

The average price target for Disc Medicine is 112.71. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $153.00 ,the lowest forecast is $90.00. The average price target represents 25.32% Increase from the current price of $89.94.

What do analysts say about Disc Medicine?

Disc Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of IRON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Disc Medicine (IRON) Stock Forecast & Price Target

IRON Analyst Ratings

IRON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Disc Medicine

IRON Analyst Recommendation Trends

IRON Financial Forecast

IRON Earnings Forecast

IRON Sales Forecast

IRON Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts